Financial insights of VTVT

MyFinsight

For the year ending 2025-12-31.

Income Statement	2025-12-31
Revenue	0
Research and development	17,861,000
General and administrative	14,947,000
Total operating expenses	32,808,000
Operating loss	-32,808,000
Other (expense) income, net-Nonrelated Party	-109,000
Other (expense) income, net-Related Party	-27,000
Interest income	1,870,000
Interest expense	6,000
Loss before income taxes and noncontrolling interest	-31,080,000
U.s. statutory tax benefit	-6,527,000
Change in valuation allowance	6,925,000
Tax credits	323,000
Other	75,000
Income tax provision	0
Net loss before noncontrolling interest	-31,080,000
Net loss attributable to noncontrolling interest	-4,106,000
Net loss attributable to vtv therapeutics inc	-26,974,000

Basic EPS	-3.2
Diluted EPS	-3.2
Basic Average Shares	8,423,632
Diluted Average Shares	8,423,632